Morgan Stanley has upgraded PTC Therapeutics (PTCT), while downgrading Immuneering (IMRX) and Amicus Therapeutics (FOLD).

Key Takeaways Morgan Stanley kept Apple as its "Top Pick" for 2025 as the bank sees the tech giant's artificial intelligence ...

Morgan Stanley Direct Lending Fund offers a 10% dividend yield and a low-risk portfolio. Read why MSDL would be an appealing ...

Morgan Stanley is close to an agreement to buy around €900 million ($940 million) in Spanish mortgages from Banco Santander ...

Sempra (NYSE:SRE) +1.5% in Friday's trading as Morgan Stanley upgrades to Overweight from Equal Weight with a $98 price ...

Nomura Holdings Inc. and Morgan Stanley are set to launch currency market-making services in India, according to people ...

The U.S. Securities and Exchange Commission said that Morgan Stanley failed to detect hundreds of unauthorized transfers that ...

The bank failed to detect “hundreds” of instances when brokers misappropriated client funds through unauthorized Automated ...

Funds managed by Igneo Infrastructure Partners are buying out Morgan Stanley’s 50% stake in Norwegian liquefied natural gas ...

Morgan Stanley Smith Barney will pay a $15 million penalty as part of a settlement with the Securities and Exchange ...

Morgan Stanley sees potential growth in technology, natural gas, and defense sectors under Trump's 2024 win but flags risks ...

We recently published a list of Top 15 AI Stock News and Ratings Dominating Wall Street. In this article, we are going to ...